Reply to Yap et al: re: Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, May 02, 2016

Reply to Yap et al: re: Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development



Reply to Yap et al

 ....The examples of poly (ADP-ribose) polymerase inhibitors are specifically mentioned in the correspondence.3 As noted in our original article, the maximum-tolerated dose, 400 mg twice daily, was subsequently used for further development.4 This dose and schedule were not based on the limited data from serial tumor biopsies (four patients at 200 to 400 mg, all with evidence of target inhibition) presented in that study. Notably, there was an apparent relationship between dose and response in BRCA-mutant patients with ovarian cancer, with greatest efficacy at the dose of 400 mg twice daily. Thus, the pharmacodynamic studies, although scientifically elegant, did not impact the choice of dose or the decision to advance the drug......

Related Article


REFERENCES

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.

Related Article

0 comments :

Post a Comment

Your comments?